Jim Cramer's 'Mad Money' CEO Chats: Edwards Lifesciences and Galena Biopharma
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener .
NEW YORK ( TheStreet) -- Every night, Jim Cramer sits down with CEOs and executives on his "Mad Money" show to discuss their business, the economy, politics and more. Today we look back at his recent interviews with Michael Mussallem, chairman and CEO of Edwards Lifesciences
These are excerpts from Cramer's 'Mad Money' Recap, originally published on Jan. 15 and Jan. 16, 2014.
Executive Decision: Michael Mussallem
For his second "Executive Decision" segment, Cramer spoke with Michael Mussallem, chairman and CEO of Edwards Lifesciences, one of last year's laggards that is now up 7% so far in 2014.
Mussallem commented on his company's recent legal win against Medtronic
Mussallem continued that Edwards has always been an innovator, inventing in the technology that allows heart value implants without the need for open-heart surgery.
When asked why the company lowered expectations for Wall Street analysts, Mussallem said there was never a question if competition was coming, only when, and now that its here, it's only prudent to be realistic.
That said, Mussallem touted his company's new "Sapien 3" technology as the next generation of treatments, something the competition will not be able to mimic for quite some time.
Cramer said that Edwards has a lot of great technology and last year's laggards may just be this year's big winners.
Executive Decision: Mark Ahn
For his "Executive Decision" segment, Cramer spoke with Dr. Mark Ahn, president and CEO of Galena Biopharma, a smaller, speculative biotech company that's showing a lot of promise with its NeuVax anti-cancer treatment currently in Phase III testing. Shares of Galana are up over 233% since November.
Ahn said Galena has seen exciting and promising results from its studies so far, which have shown either a delay or prevention of cancer recurrence. He said the company has a multi-billion dollar opportunity, both for breast cancer as well as gastric cancer and as a standalone and combination treatment with other drugs.
When asked about delays in getting the Phase III stuff off the ground, Ahn said it takes time to set up the 130 hospitals in 15 countries that will be testing the drug, but the study will be fully enrolled by mid year.
Ahn also responded to critics who charge Galena is ignoring the fact that NeuVax may not help, and may even harm, some patients. He said it's totally appropriate for any new drug to have its skeptics, and that NeuVax, like every drug, has a segment of patients for which it is most effective and others where it's not effective. In Phase II testing NeuVax saw 0% cancer recurrence, and that's what the company is now testing in Phase III.